Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EU-AIMS

Financiado

Cerrado

European Autism Interventions - A Multicentre Study for Developing New Medicatio...

European Autism Interventions - A Multicentre Study for Developing New Medications Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of ae... ver más

31/03/2018

ROCHE

37M€

Presupuesto del proyecto: 37M€

Líder del proyecto

F. HOFFMANNLA ROCHE AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 20 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2018-03-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

20 Participantes

ROCHE

Lider

Pfizer RD UK Limited

N.D. | Participante

THE CHANCELLOR MASTERS AND S...

N.D. | Participante

NOLDUS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EU-AIMS European Autism Interventions A Multicentre Study for Deve... 37M€ Cerrado

NEWMEDS Novel Methods leading to New Medications in Depression and S... 25M€ Cerrado

DUPDOWN Deacetylase inhibitors for autism spectrum disorders an int... 150K€ Cerrado

ASCTN-Training Training on Advanced Stem Cell Technologies in Neurology 4M€ Cerrado

PCI2019-103712 ALTERACION DE LA COMUNICACION ESPACIO-TEMPORAL ENTRE NEURONA... 190K€ Cerrado

Duración del proyecto: 71 meses Fecha Inicio: 2012-04-01
Fecha Fin: 2018-03-31

Líder del proyecto

F. HOFFMANNLA ROCHE AG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 37M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories which provide a collection of biologically heterogeneous patients. Further, even if novel treatments are developed there is no EU platform to clinically test them. Our hypothesis is that a focus on cross-species endophenotypes, finding biologically-homogenous groups of patients, and developing a clinical research network will overcome the limitations in target identification, early triage and clinical trials. Hence, leading European institutions and three SMEs will partner with the EFPIA to: a) develop in vitro models, and animal models that carry confirmed genetic risks, and in these animals to focus on cross-species endophenotypes (e.g., cognitive function, electrophysiology) to facilitate new drug discovery; b) validate the use of sMRI and fMRI-based endophenotypes in genetically-selected healthy volunteers, infants at risk for ASD, and children and adults (including twins) with and without ASD, as early and surrogate markers for efficacy; and to combine this with PET approaches to provide guidance regarding optimal clinical trial design; and c) identify biomarkers that can be used to stratify patients within an umbrella DSM-diagnosis, thus allowing for targeted clinical trials, individualized treatment and back-translation of subgroup-specific biomarkers into preclinical drug discovery. To increase the chance of a breakthrough we will implement new analytical approaches (e.g. support vector machine learning algorithms) and will actively collaborate with patient groups and other international efforts (e.g. the Autism Genetic Resource Exchange (AGRE)).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores